Annals of Surgical Oncology

, Volume 14, Issue 11, pp 3188–3194 | Cite as

Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin

  • Dominique Elias
  • Diane Goere
  • Valérie Boige
  • Niaz Kohneh-Sharhi
  • David Malka
  • Gorana Tomasic
  • Clarisse Dromain
  • Michel Ducreux
Thoracic Oncology

Abstract

Background

Dramatic responses to chemotherapy are occurring more and more frequently in patients with multiple colorectal liver metastases (LMs), leading to resection. In a few patients, some LMs vanish on imaging studies, remain undetected during hepatectomy, and are left in place, which defines the “missing LMs.” The aim of our study was to assess the long-term outcome of such “missing LMs.”

Patients

Between January 1999 and June 2004, among 228 patients treated for colorectal LMs, missing LMs were observed in 16 patients. All the patients were operated within 4 weeks of imaging. Hepatic arterial infusion (HAI) with oxaliplatin was administrated in 12 patients (75%): seven before hepatectomy and five after.

Results

Overall, 69 missing LMs were diagnosed and left in place. Among the persistent LMs resected, a complete pathological response was significantly more often observed in the group with preoperative HAI (6 of 7), than in the group without (2 of 9, P < .02). With a mean follow-up of 51 months (24–90), missing LMs did not reappear in 10 patients (62%). Adjuvant HAI was significantly correlated with the definitive eradication of missing LMs (P < .01), as it was not a complete pathological response. The overall 3-year survival rate of these highly selected 16 patients was 94%.

Conclusion

Colorectal LMs under chemotherapy that vanish on high-quality imaging studies, remain undetected during hepatectomy, and are left in place, are definitively cured in 62% of cases. This excellent result seems to be due to the administration of adjuvant hepatic arterial infusion of chemotherapy and should stimulate new investigations.

Keywords

Missing metastases Colorectal cancer Chemotherapy Complete response Liver metastases Intra-arterial chemotherapy Hepatectomy Oxaliplatin 

Notes

ACKNOWLEDGMENT

The authors thank Lorna Saint Ange for editing.

REFERENCES

  1. 1.
    Ducreux M, Ychou M, Laplanche A, Gamelin, Lasser P, Husseini F, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the FNLCC. J Clin Oncol 2005;23:4881–7Google Scholar
  2. 2.
    Elias D, Lasser P, de Baere B, Doidy L, Billard V, Spencer A, et al. Intermittent exclusion of the liver without vena cava clamping during major hepatectomy. Br J Surg 1995;82:1535–9PubMedCrossRefGoogle Scholar
  3. 3.
    Elias D, Roche A, Vavasseur D, Lasser Ph. Induction d’une hypertrophie d’un petit lobe gauche hépatique avant hépatectomie droite élargie, par embolisation portale droite pré-opératoire. Ann Chir 1992;46:404–10PubMedGoogle Scholar
  4. 4.
    Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052–61PubMedCrossRefGoogle Scholar
  5. 5.
    Allen PJ, Kemeny N, Jarnagin W, de Matteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003;7:109–15PubMedCrossRefGoogle Scholar
  6. 6.
    Adam R, Avisar A, Giachetti S, Azoulay D, Castaing D, Kustlinger F, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal liver metastases. Ann Surg Oncol 2001;8:347–53PubMedCrossRefGoogle Scholar
  7. 7.
    O’Connell MJ, Nagorney DM, Bernath AM, Schoeder G, Fitzgibbons RJ, Mailliard JA, et al. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 1998;16:2528–33PubMedGoogle Scholar
  8. 8.
    Porta C, Danova M, Accurso S, Tinelli C, Girino M, Ricardi A, et al. Sequential intrahepatic and systemic fluoroperimidine-based chemotherapy for metastatic colorectal cancer confined to the liver: a phase II study. Cancer Chemother Pharmacol 2001; 47:423–8PubMedCrossRefGoogle Scholar
  9. 9.
    Maire F, Malka D, Elias D, Boige V, Lièvre A, Louafi S, et al. Hepatic arterial infusion oxaliplatin and intravenous LV5FU2 after resection of colorectal liver metastases. Eur J Cancer 2005; 3, Vol 2: p 190; A670Google Scholar
  10. 10.
    Elias D, Youssef O, Dideris L, Dromain C, Baton O, Boige V, et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 2004;86(1):4–9PubMedCrossRefGoogle Scholar
  11. 11.
    Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, et al. Complete radiological response of colorectal liver metastasis (LM) after chemotherapy: does it mean cure? J Clin Oncol 2006;24:3939–44PubMedCrossRefGoogle Scholar
  12. 12.
    Hobday TJ, Cha SS, Sargent DJ, Buroker TR, O’Connell MJ, Goldberg RM, et al. Long term survivors of metastatic colorectal cancer treated with chemotherapy only: a NCCTG review. Proc of ASCO 2002; 693:174aGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • Dominique Elias
    • 1
  • Diane Goere
    • 1
  • Valérie Boige
    • 2
  • Niaz Kohneh-Sharhi
    • 1
  • David Malka
    • 2
  • Gorana Tomasic
    • 3
  • Clarisse Dromain
    • 4
  • Michel Ducreux
    • 2
  1. 1.Department of Surgical OncologyInstitut Gustave RoussyVillejuifFrance
  2. 2.Department of Medical OncologyInstitut Gustave RoussyVillejuifFrance
  3. 3.Department of PathologyInstitut Gustave RoussyVillejuifFrance
  4. 4.Department of RadiologyInstitut Gustave RoussyVillejuifFrance

Personalised recommendations